Lasorin nasal spray 1.18 mg/ml 10 ml can with dosing device

For the relief of nasal congestion associated with acute rhinitis, vasomotor rhinitis and allergic rhinitis.

To facilitate the discharge of secretions in sinusitis and otitis media associated with acute rhinitis.

Hypersensitivity to tramazoline hydrochloride or to any of the excipients of the drug.

Glaucoma.

Dry rhinitis.

Contraindicated in patients who have undergone transnasal intracranial surgery.

Spray 1 dose into each nostril up to 3 times daily as needed. Dosage is determined based on individual sensitivity and clinical response.

Lasorin should be used for short-term treatment of acute symptoms for no more than 5-7 days.

In all other cases, according to indications and for all indications for use in children, a physician’s assessment of the benefit/risk ratio is required.

A break of several days should be taken between individual periods of treatment.

Children

Use for children aged 6 and over.

Use during pregnancy or breastfeeding

During preclinical studies, no evidence of harmful effects of the drug on the embryo was found.

LASORIN should not be used in the first trimester of pregnancy.

In the II and III trimesters of pregnancy and during breastfeeding, the drug should be used only as prescribed by a doctor.

Active ingredient: tramazoline; 1 ml of solution contains 1.265 mg of tramazoline hydrochloride monohydrate, which corresponds to 1.18 mg of tramazoline hydrochloride.

Excipients: citric acid monohydrate, sodium hydroxide, benzalkonium chloride, hydroxypropylmethylcellulose, povidone, glycerin (85%), magnesium sulfate heptahydrate, magnesium chloride hexahydrate, calcium chloride dihydrate, sodium bicarbonate, sodium chloride, eucalyptol, menthol, camphor, purified water.

Store at a temperature not exceeding 25 °C in a place inaccessible to children.